Hospitals dominated the end-user segment with a market share of 44.26% in 2025, driven by high patient volumes, increasing diabetes management programs, growing obesity treatment initiatives, and greater access to specialist endocrinology services
as of 2024, it has not received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA) for use in the United Kingdom or European Union
They create a better foundation for energy, mood, and long-term wellness
Medical weight loss is a physician-guided weight loss service that may include GLP-1 medications such as semaglutide and tirzepatide alongside a personalized plan
In doing so, we answer the question, Why do we become obese? The second half of this chapter explores the pathophysiology of obesity-related metabolic disease and the effects of nutrient excess on cellular metabolism and systemic physiology, answering the question, Why does obesity make us sick ? Access this chapter Subscribe and save Buy Now Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others References Friedman JM
Full therapeutic effects may take 12 weeks or longer at a stable maintenance dose
